Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...
Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...
Chinese biotech Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) has entered into a collaboration and licensing agreement with ...
Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...
In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
GlobalData on MSN8d
Innovent and Roche link on lung cancer therapy developmentInnovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a ...
Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...
Analyst Jill Wu of CMB International Securities maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), boosting the price ...
SAN FRANCISCO and SUZHOU, China, Jan. 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
Developed leveraging Innovent's proprietary novel topoisomerase 1 inhibitor (TOPO1i) platform, IBI3009 is one of the leading and potentially best-in-class DLL3-targeting ADCs. IBI3009 has shown ...
Innovent Biologics (HK:1801) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback